{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:55:35Z","timestamp":1794408935154,"version":"4.9.0"},"reference-count":146,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T00:00:00Z","timestamp":1432252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Boehringer Ingelheim"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during human development and reproduction; however, aberrant regulation of angiogenesis is also a fundamental process found in several pathologic conditions, including cancer. As a process required for invasion and metastasis, tumor angiogenesis constitutes an important point of control of cancer progression. Although not yet completely understood, the complex process of tumor angiogenesis involves highly regulated orchestration of multiple signaling pathways. The proangiogenic signaling molecule vascular endothelial growth factor (VEGF) and its cognate receptor (VEGF receptor 2 [VEGFR-2]) play a central role in angiogenesis and often are highly expressed in human cancers, and initial clinical efforts to develop antiangiogenic treatments focused largely on inhibiting VEGF\/VEGFR signaling. Such approaches, however, often lead to transient responses and further disease progression because angiogenesis is regulated by multiple pathways that are able to compensate for each other when single pathways are inhibited. The platelet-derived growth factor (PDGF) and PDGF receptor (PDGFR) and fibroblast growth factor (FGF) and FGF receptor (FGFR) pathways, for example, provide potential escape mechanisms from anti-VEGF\/VEGFR therapy that could facilitate resumption of tumor growth. Accordingly, more recent treatments have focused on inhibiting multiple signaling pathways simultaneously. This comprehensive review discusses the limitations of inhibiting VEGF signaling alone as an antiangiogenic strategy, the importance of other angiogenic pathways including PDGF\/PDGFR and FGF\/FGFR, and the novel current and emerging agents that target multiple angiogenic pathways for the treatment of advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice:<\/jats:title>\n                    <jats:p>Significant advances in cancer treatment have been achieved with the development of antiangiogenic agents, the majority of which have focused on inhibition of the vascular endothelial growth factor (VEGF) pathway. VEGF targeting alone, however, has not proven to be as efficacious as originally hoped, and it is increasingly clear that there are many interconnected and compensatory pathways that can overcome VEGF-targeted inhibition of angiogenesis. Maximizing the potential of antiangiogenic therapy is likely to require a broader therapeutic approach using a new generation of multitargeted antiangiogenic agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0465","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T22:51:05Z","timestamp":1432335065000},"page":"660-673","source":"Crossref","is-referenced-by-count":490,"title":["Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor"],"prefix":"10.1093","volume":"20","author":[{"given":"Yujie","family":"Zhao","sequence":"first","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,5,22]]},"reference":[{"key":"2021122309231697900_B1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: An organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nature Rev Drug Discov"},{"key":"2021122309231697900_B2","doi-asserted-by":"crossref","first-page":"a006593","DOI":"10.1101\/cshperspect.a006593","article-title":"The VEGF pathway in cancer and disease: Responses, resistance, and the path forward","volume":"2","author":"Kieran","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2021122309231697900_B3","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"2021122309231697900_B5","volume-title":"Avastin [prescribing information]","year":"2014"},{"key":"2021122309231697900_B6","volume-title":"Inlyta [package insert]","year":"2013"},{"key":"2021122309231697900_B7","volume-title":"Cyramza [package insert]","year":"2014"},{"key":"2021122309231697900_B8","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"2021122309231697900_B9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/0006-291X(89)92729-0","article-title":"Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family","volume":"165","author":"Tischer","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122309231697900_B10","doi-asserted-by":"crossref","first-page":"re1","DOI":"10.1126\/scisignal.259re1","article-title":"Positive and negative modulation of angiogenesis by VEGFR1 ligands","volume":"2","author":"Cao","year":"2009","journal-title":"Sci Signal"},{"key":"2021122309231697900_B11","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B12","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nrc2524","article-title":"FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy?","volume":"8","author":"Fischer","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2021122309231697900_B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3858\/emm.2012.44.1.025","article-title":"The discovery of placenta growth factor and its biological activity","volume":"44","author":"De Falco","year":"2012","journal-title":"Exp Mol Med"},{"key":"2021122309231697900_B14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cell.2010.01.045","article-title":"Lymphangiogenesis: Molecular mechanisms and future promise","volume":"140","author":"Tammela","year":"2010","journal-title":"Cell"},{"key":"2021122309231697900_B15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"2021122309231697900_B16","volume-title":"FDA commissioner announces Avastin decision","year":"2015"},{"key":"2021122309231697900_B17","doi-asserted-by":"crossref","first-page":"23024","DOI":"10.3390\/ijms151223024","article-title":"Anti-vascular endothelial growth factor therapy in breast cancer","volume":"15","author":"Kristensen","year":"2014","journal-title":"Int J Mol Sci"},{"key":"2021122309231697900_B18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/107327481201900407","article-title":"Lessons learned from the bevacizumab experience","volume":"19","author":"Mortimer","year":"2012","journal-title":"Cancer Contr"},{"key":"2021122309231697900_B19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2012.03.008","article-title":"Anti-angiogenesis therapy in cancer: Current challenges and future perspectives","volume":"320","author":"Shojaei","year":"2012","journal-title":"Cancer Lett"},{"key":"2021122309231697900_B20","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","article-title":"Rapid vascular regrowth in tumors after reversal of VEGF inhibition","volume":"116","author":"Mancuso","year":"2006","journal-title":"J Clin Invest"},{"key":"2021122309231697900_B21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"2021122309231697900_B22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122309231697900_B23","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/bjc.2011.85","article-title":"Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer","volume":"104","author":"Loupakis","year":"2011","journal-title":"Br J Cancer"},{"key":"2021122309231697900_B24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1345\/aph.1L426","article-title":"Intricacies of bevacizumab-induced toxicities and their management","volume":"43","author":"Gressett","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2021122309231697900_B25","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: A VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309231697900_B26","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1215\/15228517-2008-061","article-title":"VEGF Trap induces antiglioma effect at different stages of disease","volume":"10","author":"Gomez-Manzano","year":"2008","journal-title":"Neuro Oncol"},{"key":"2021122309231697900_B27","doi-asserted-by":"crossref","first-page":"11399","DOI":"10.1073\/pnas.172398399","article-title":"Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma","volume":"99","author":"Kim","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309231697900_B28","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"2021122309231697900_B30","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122309231697900_B31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11912-010-0149-5","article-title":"Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2","volume":"13","author":"Spratlin","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"2021122309231697900_B32","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s40265-013-0154-8","article-title":"Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: From benchside to clinical use","volume":"73","author":"Aprile","year":"2013","journal-title":"Drugs"},{"key":"2021122309231697900_B33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"2021122309231697900_B34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2014.57.1513","article-title":"Primary results of ROSE\/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","volume":"33","author":"Mackey","year":"2015","journal-title":"J Clin Oncol"},{"issue":"(suppl 5)","key":"2021122309231697900_B35","first-page":"LBA16a","article-title":"Ramucirumab (RAM) as a second-line treatment in patients (PTS) with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: Results from the randomized phase III REACH study","volume":"25","author":"Zhu","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309231697900_B36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cytogfr.2009.11.003","article-title":"Pathways mediating VEGF-independent tumor angiogenesis","volume":"21","author":"Ferrara","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"2021122309231697900_B37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1478-811X-11-97","article-title":"Targeting the PDGF signaling pathway in tumor treatment","volume":"11","author":"Heldin","year":"2013","journal-title":"Cell Commun Signal"},{"key":"2021122309231697900_B38","doi-asserted-by":"crossref","first-page":"e3794","DOI":"10.1371\/journal.pone.0003794","article-title":"Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells","volume":"3","author":"Wu","year":"2008","journal-title":"PLoS One"},{"key":"2021122309231697900_B39","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2013.05.002","article-title":"Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis","volume":"19","author":"Cao","year":"2013","journal-title":"Trends Mol Med"},{"key":"2021122309231697900_B40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cytogfr.2004.03.010","article-title":"PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases","volume":"15","author":"Levitzki","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"2021122309231697900_B41","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/1078-0432.CCR-05-1770","article-title":"Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma","volume":"12","author":"Tejada","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309231697900_B42","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2010-02-269894","article-title":"Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: Implications for an angiogenic switch","volume":"116","author":"Ding","year":"2010","journal-title":"Blood"},{"key":"2021122309231697900_B43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2004.08.034","article-title":"PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis","volume":"6","author":"Cao","year":"2004","journal-title":"Cancer Cell"},{"key":"2021122309231697900_B44","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1349-7006.2010.01639.x","article-title":"Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor \u03b2 is associated with lymphatic metastasis in human gastric carcinoma","volume":"101","author":"Kodama","year":"2010","journal-title":"Cancer Sci"},{"key":"2021122309231697900_B45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm.2575","article-title":"PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells","volume":"18","author":"Xue","year":"2012","journal-title":"Nat Med"},{"key":"2021122309231697900_B46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4161\/cbt.9.3.10635","article-title":"Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models","volume":"9","author":"Lu","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"2021122309231697900_B47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: Biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"2021122309231697900_B48","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res"},{"key":"2021122309231697900_B49","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00109-008-0337-z","article-title":"R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways","volume":"86","author":"Cao","year":"2008","journal-title":"J Mol Med (Berl)"},{"key":"2021122309231697900_B50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1471-4914(02)02394-8","article-title":"The role of fibroblast growth factors in vascular development","volume":"8","author":"Javerzat","year":"2002","journal-title":"Trends Mol Med"},{"key":"2021122309231697900_B51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cytogfr.2005.01.004","article-title":"Fibroblast growth factor\/fibroblast growth factor receptor system in angiogenesis","volume":"16","author":"Presta","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"2021122309231697900_B52","doi-asserted-by":"crossref","first-page":"15894","DOI":"10.1073\/pnas.1208324109","article-title":"Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis","volume":"109","author":"Cao","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309231697900_B53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrc2894","article-title":"Targeting the ANGPT-TIE2 pathway in malignancy","volume":"10","author":"Huang","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2021122309231697900_B54","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0002-9440(10)64325-8","article-title":"Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis","volume":"162","author":"Giavazzi","year":"2003","journal-title":"Am J Pathol"},{"key":"2021122309231697900_B55","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"2021122309231697900_B56","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.2011.38.7621","article-title":"Targeting the angiopoietin\/Tie2 pathway: Cutting tumor vessels with a double-edged sword?","volume":"30","author":"Cascone","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.1618","article-title":"Angiopoietins in tumours: The angiogenic switch","volume":"204","author":"Tait","year":"2004","journal-title":"J Pathol"},{"key":"2021122309231697900_B58","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/0008-5472.CAN-12-4697","article-title":"Angiopoietin-2: An attractive target for improved antiangiogenic tumor therapy","volume":"73","author":"Gerald","year":"2013","journal-title":"Cancer Res"},{"key":"2021122309231697900_B59","doi-asserted-by":"crossref","first-page":"a009209","DOI":"10.1101\/cshperspect.a009209","article-title":"MET: A critical player in tumorigenesis and therapeutic target","volume":"5","author":"Graveel","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2021122309231697900_B60","doi-asserted-by":"crossref","first-page":"833","DOI":"10.5483\/BMBRep.2008.41.12.833","article-title":"The hepatocyte growth factor\/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis","volume":"41","author":"You","year":"2008","journal-title":"BMB Rep"},{"key":"2021122309231697900_B61","first-page":"427","article-title":"Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells","volume":"79","author":"Wojta","year":"1999","journal-title":"Lab Invest"},{"key":"2021122309231697900_B62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2012.05.037","article-title":"VEGF inhibits tumor cell invasion and mesenchymal transition through a MET\/VEGFR2 complex","volume":"22","author":"Lu","year":"2012","journal-title":"Cancer Cell"},{"key":"2021122309231697900_B63","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/1078-0432.CCR-12-1281","article-title":"Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance","volume":"19","author":"Jahangiri","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122309231697900_B64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: Expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2021122309231697900_B65","doi-asserted-by":"crossref","first-page":"a009134","DOI":"10.1101\/cshperspect.a009134","article-title":"Structure and physiology of the RET receptor tyrosine kinase","volume":"5","author":"Ib\u00e1\u00f1ez","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2021122309231697900_B66","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B67","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B68","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B69","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1183\/09059180.00008913","article-title":"Therapeutic options targeting angiogenesis in nonsmall cell lung cancer","volume":"23","author":"Crin\u00f2","year":"2014","journal-title":"Eur Respir Rev"},{"key":"2021122309231697900_B70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/OTT.S18155","article-title":"Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC","volume":"4","author":"Ballas","year":"2011","journal-title":"Onco Targets Ther"},{"key":"2021122309231697900_B71","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1172\/JCI70212","article-title":"Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer","volume":"123","author":"Welti","year":"2013","journal-title":"J Clin Invest"},{"key":"2021122309231697900_B72","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","article-title":"Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance","volume":"28","author":"Kopetz","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B73","doi-asserted-by":"crossref","first-page":"e77117","DOI":"10.1371\/journal.pone.0077117","article-title":"The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer","volume":"8","author":"Lieu","year":"2013","journal-title":"PLoS One"},{"key":"2021122309231697900_B74","first-page":"253","article-title":"Understanding and targeting resistance to anti-angiogenic therapies","volume":"4","author":"Clarke","year":"2013","journal-title":"J Gastrointest Oncol"},{"key":"2021122309231697900_B75","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","article-title":"Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis","volume":"8","author":"Ebos","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122309231697900_B76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2009.02.007","article-title":"Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited","volume":"15","author":"Loges","year":"2009","journal-title":"Cancer Cell"},{"key":"2021122309231697900_B77","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J Clin Invest"},{"key":"2021122309231697900_B78","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"key":"2021122309231697900_B79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"2021122309231697900_B80","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.mri.2006.09.041","article-title":"AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging","volume":"25","author":"Wilmes","year":"2007","journal-title":"Magn Reson Imaging"},{"key":"2021122309231697900_B81","volume-title":"Cometriq [package insert]","year":"2012"},{"key":"2021122309231697900_B82","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"2021122309231697900_B83","volume-title":"Votrient [package insert]","year":"2013"},{"key":"2021122309231697900_B84","volume-title":"Stivarga [package insert]","year":"2013"},{"key":"2021122309231697900_B85","volume-title":"Nexavar [package insert]","year":"2013"},{"key":"2021122309231697900_B86","volume-title":"Sutent [package insert]","year":"2013"},{"key":"2021122309231697900_B87","volume-title":"Caprelsa [package insert]","year":"2013"},{"key":"2021122309231697900_B88","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/1078-0432.CCR-12-2353","article-title":"Vandetanib for the treatment of medullary thyroid cancer","volume":"19","author":"Chau","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122309231697900_B89","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"2021122309231697900_B90","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122309231697900_B91","doi-asserted-by":"crossref","first-page":"8034a","DOI":"10.1200\/jco.2013.31.15_suppl.8034","article-title":"LUME-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy","volume":"31","author":"Hanna","year":"2013","journal-title":"J Clin Oncol"},{"issue":"(suppl 1)","key":"2021122309231697900_B92","first-page":"7","article-title":"AGO-OVAR 12: A randomized placebo-controlled GCIG\/ENGOT-intergroup phase III trial of standard frontline chemotherapy +\/\u2212 nintedanib for advanced ovarian cancer","volume":"23","author":"Du Bois","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"2021122309231697900_B93","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B94","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"2021122309231697900_B95","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"2021122309231697900_B96","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"2021122309231697900_B97","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B98","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122309231697900_B99","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2021122309231697900_B100","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-11-3005","article-title":"Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure","volume":"18","author":"Demetri","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122309231697900_B101","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122309231697900_B102","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122309231697900_B103","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: Final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021122309231697900_B104","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-12-0002","article-title":"Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients","volume":"18","author":"Griffioen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122309231697900_B105","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejphar.2013.02.026","article-title":"Study of the cellular mechanism of sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis","volume":"705","author":"Majumder","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"2021122309231697900_B106","doi-asserted-by":"crossref","first-page":"E1275","DOI":"10.1073\/pnas.1111079108","article-title":"Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma","volume":"108","author":"Olson","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309231697900_B107","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309231697900_B108","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1158\/1535-7163.MCT-06-0595","article-title":"Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice","volume":"6","author":"Kim","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"2021122309231697900_B109","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"2021122309231697900_B110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","article-title":"(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor","volume":"15","author":"Hamberg","year":"2010","journal-title":"The Oncologist"},{"key":"2021122309231697900_B111","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","article-title":"Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model","volume":"12","author":"Abou-Elkacem","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2021122309231697900_B112","doi-asserted-by":"crossref","first-page":"e76009","DOI":"10.1371\/journal.pone.0076009","article-title":"Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation","volume":"8","author":"Cyran","year":"2013","journal-title":"PLoS One"},{"key":"2021122309231697900_B113","volume-title":"CHMP summary of positive opinion for Vargatef","year":"2015"},{"key":"2021122309231697900_B114","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-09-0694","article-title":"Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors","volume":"16","author":"Mross","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122309231697900_B115","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/13543784.2010.488220","article-title":"BIBF 1120 for the treatment of non-small cell lung cancer","volume":"19","author":"Reck","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122309231697900_B116","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-10-0379","article-title":"Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors","volume":"9","author":"Okamoto","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2021122309231697900_B117","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-09-2755","article-title":"Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo","volume":"17","author":"Kudo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122309231697900_B118","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s10637-013-9962-7","article-title":"Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study","volume":"31","author":"Eisen","year":"2013","journal-title":"Invest New Drugs"},{"key":"2021122309231697900_B119","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/annonc\/mdr596","article-title":"A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer","volume":"23","author":"Doebele","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122309231697900_B120","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/bjc.2011.440","article-title":"Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients","volume":"105","author":"Bousquet","year":"2011","journal-title":"Br J Cancer"},{"key":"2021122309231697900_B121","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1158\/1078-0432.CCR-09-2944","article-title":"Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients","volume":"16","author":"Ellis","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122309231697900_B122","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdp506","article-title":"A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies","volume":"21","author":"Bois","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122309231697900_B123","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B124","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1021\/jm7013309","article-title":"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)","volume":"51","author":"Cai","year":"2008","journal-title":"J Med Chem"},{"key":"2021122309231697900_B125","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","article-title":"AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer","volume":"65","author":"Wedge","year":"2005","journal-title":"Cancer Res"},{"key":"2021122309231697900_B126","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-12-2885","article-title":"Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma","volume":"19","author":"Angevin","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122309231697900_B127","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122309231697900_B128","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"key":"2021122309231697900_B129","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-8722-2-33","article-title":"ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside","volume":"2","author":"Zhou","year":"2009","journal-title":"J Hematol Oncol"},{"key":"2021122309231697900_B131","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2012.42.6031","article-title":"Cediranib plus FOLFOX\/CAPOX versus placebo plus FOLFOX\/CAPOX in patients with previously untreated metastatic colorectal cancer: A randomized, double-blind, phase III study (HORIZON II)","volume":"30","author":"Hoff","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B132","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1200\/JCO.2012.42.5355","article-title":"Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III)","volume":"30","author":"Schmoll","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B133","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B134","article-title":"Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial [abstract E17-7020]","volume-title":"Presented at: ECCO-ESMO-ESTRO European Cancer Congress","author":"Ledermann","year":"2013"},{"key":"2021122309231697900_B135","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejca.2013.11.032","article-title":"Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29","volume":"50","author":"Laurie","year":"2014","journal-title":"Eur J Cancer"},{"key":"2021122309231697900_B136","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122309231697900_B137","doi-asserted-by":"crossref","first-page":"LBA6008a","DOI":"10.1200\/jco.2014.32.18_suppl.lba6008","article-title":"A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)","volume":"32","author":"Schlumberger","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309231697900_B138","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/00498254.2010.545452","article-title":"Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers","volume":"41","author":"Stopfer","year":"2011","journal-title":"Xenobiotica"},{"key":"2021122309231697900_B139","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2217\/fon.12.73","article-title":"Cediranib: A VEGF receptor tyrosine kinase inhibitor","volume":"8","author":"Sahade","year":"2012","journal-title":"Future Oncol"},{"key":"2021122309231697900_B140","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/13543784.2014.871259","article-title":"Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma","volume":"23","author":"Sonpavde","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122309231697900_B141","doi-asserted-by":"crossref","first-page":"830","DOI":"10.4254\/wjh.v6.i12.830","article-title":"Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out","volume":"6","author":"Sun","year":"2014","journal-title":"World J Hepatol"},{"key":"2021122309231697900_B142","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1758834012458480","article-title":"New agents on the horizon in hepatocellular carcinoma","volume":"5","author":"Zhu","year":"2013","journal-title":"Ther Adv Med Oncol"},{"key":"2021122309231697900_B143","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(14)70444-9","article-title":"Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): A randomised, open-label, phase 3 trial","volume":"15","author":"Gligorov","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122309231697900_B144","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","article-title":"Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial","volume":"15","author":"Von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122309231697900_B145","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.3390\/ijms14059338","article-title":"Biomarkers for anti-angiogenic therapy in cancer","volume":"14","author":"Wehland","year":"2013","journal-title":"Int J Mol Sci"},{"key":"2021122309231697900_B146","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.2174\/13816128113196660757","article-title":"Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: A \u2018hard days night\u2019","volume":"20","author":"Pilotto","year":"2014","journal-title":"Curr Pharm Des"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0465","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/6\/660\/41869529\/oncolo_20_6_660.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/6\/660\/41869529\/oncolo_20_6_660.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T21:35:48Z","timestamp":1640295348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/6\/660\/6399659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,22]]},"references-count":146,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,5,22]]},"published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0465","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,6,1]]},"published":{"date-parts":[[2015,5,22]]}}}